Capstone Development Services Co. LLC

BILLERICA, Mass.--( BUSINESS WIRE )-- Access Vascular, Inc. (AVI), a leader in tackling critical vascular access challenges with its advanced hydrophilic biomaterial technology, today announced a strategic partnership with Capstone Health Alliance, a prominent regional group purchasing organization (GPO). This collaboration will extend access to Access Vascular's cutting-edge MIMIX ® hydrophilic catheters for Capstone’s expansive network of more than 300 hospitals, independent health systems, and physician practices across the U.S. Access Vascular developed the MIMIX ® line of hydrophilic biomaterial catheters, specifically designed to improve patient outcomes in IV therapy, including the HydroMID ® midline catheter and the HydroPICC ® peripherally inserted central catheter (PICC). These innovative devices are crafted from a unique biomaterial that emulates the natural chemistry of the human body, addressing the common complications associated with traditional catheter use. “Capstone is excited to partner with Access Vascular, as they understand the meaning behind value-based healthcare focused on improving clinical outcomes,” offered Anita Zado, Vice President of Clinical Services of Capstone. “As hospitals are driven to move away from finding savings at the SKU level and toward driving value with innovative outcome-based products, we are pleased to work with Access Vascular not just as a Supplier, but as an industry partner.” Clinical studies underscore the effectiveness of AVI's FDA-cleared devices, demonstrating a sixfold reduction in complications compared to standard catheters, while in vitro data showed a 99.99% reduction in bacterial adhesion. 1,2 For Capstone members, this means potential cost savings and, most importantly, improved outcomes for their patients. “Our partnership with Capstone Health Alliance accelerates our mission to improve vascular access outcomes across the country, by expanding the reach of our novel MIMIX ® catheters,” said James Biggins, founder and CEO of Access Vascular. “By lowering the incidence of catheter thrombosis, phlebitis, and infections for Capstone’s network members, this agreement will help support clinicians and improve patient care.” About Capstone Health Alliance Headquartered in Asheville, NC, Capstone Health Alliance is a leading regional group purchasing organization (GPO) that collaborates with hundreds of hospitals and thousands of healthcare providers nationwide. Our primary goal is to deliver tangible savings and provide actionable data to enable informed supply chain decisions. Capstone is committed to helping our Members reduce costs, enhance quality, and foster the exchange of best practices, through our unwavering dedication to price parity, offering consistent savings regardless of organizational size or location. Moreover, our Members gain exclusive access to educational opportunities and benefit from the expertise of our dedicated team of supply chain professionals. To learn more about Capstone Health Alliance and how our innovative solutions can benefit your organization, please visit www.capstonehealthalliance.com . About Access Vascular Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a foundationally different approach to thrombus reduction, the company manufactures intravenous catheters from a hydrophilic material. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade the foreign body response and complications that come with it. Our award-winning, FDA-cleared products are HydroPICC® and HydroMID®. For more information, please visit our website , and follow us on LinkedIn. 1 Bunch J. A retrospective assessment of peripheral midline failures focusing on catheter composition. J InfusNurs. Sept/Oct 2022; 45(5):270-27 2 LeRoy, K. J. 2023 Association for Vascular Access Scientific Meeting: Poster Abstracts. Journal of the Association for Vascular Access 1 May 2024; 29 (2): 51–66. doi: https://doi-org.libproxy1.nus.edu.sg/10.2309/1557-1289-29.2.51

Norepinephrine in 0.9% Sodium Chloride Injection will help meet critical supply reliability and patient safety needs ROSEMONT, Ill., May 22, 2024 /PRNewswire/ -- It is a New Day for Norepinephrine! Long Grove Pharmaceuticals now offers ready-to-use Norepinephrine in 0.9% Sodium Chloride in the 16 mg/250mL (64 mcg/mL) strength and anticipates the availability of the 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) strengths in early summer. Continue Reading This ready-to-use premix has a 24-month shelf life at room temperature and is safe to use up to seven days after removal from the foil overwrap. A new source for Norepinephrine is a much needed addition to the fragile critical care supply chain. The convenience and safety of this manufactured premix formulation will help hospital pharmacies focus their limited resources on addressing unique and critical patient needs. Long Grove Pharmaceuticals Launches Premix Norepinephrine Post this "We're very happy to help play a role in relieving some of the stresses that our hospital pharmacy colleagues face every day. Over the last six months, we have met with many customers who have shared their ongoing challenges and have been very supportive of our efforts to bring a safe, convenient premix Norepinephrine to market," said Peter Karas, Chief Commercial Officer of Long Grove Pharmaceuticals. Norepinephrine in 0.9% Sodium Chloride Injection is indicated to raise blood pressure in adult patients with severe, acute hypotension, and it is one of the most commonly used injectable medications in the critical care setting. For ordering information or to learn more about Long Grove Pharmaceuticals, please visit About Long Grove Pharmaceuticals Long Grove Pharmaceuticals, LLC was established in 2019 by Water Street Healthcare Partners. The company is part of Capstone Development Services, LLC, which has been developing products in partnership with the world's premier pharmaceutical and medical device organizations since 2013. Combining decades of pharmaceutical and hospital leadership experience with a portfolio of specialized, complex drug formulations, Long Grove Pharmaceuticals is delivering differentiated products that increase hospital pharmacy operational efficiency and help improve the quality of patient care. SOURCE Long Grove Pharmaceuticals

The company brings experience and agility to meet critical hospital pharmacy needs ROSEMONT, Ill., May 1, 2024 /PRNewswire/ -- Long Grove Pharmaceuticals continues to meet the critical care needs of hospital pharmacies with the launch of Premix Vasopressin in its most commonly used concentrations. Long Grove Pharmaceuticals will initially enter the market with the following concentrations of Premix Vasopressin: 20 units/100 mL (0.2 units/mL) in 0.9% sodium chloride 40 units/100 mL (0.4 units/mL) in 0.9% sodium chloride "We're focusing on the areas of greatest need in critical care, and our launch of Premix Vasopressin demonstrates this commitment. Our extensive hospital pharmacy and pharmaceutical industry experience enables us to develop differentiated pharmaceuticals designed to specifically meet key customer and patient needs," said Peter Karas, Chief Commercial Officer at Long Grove Pharmaceuticals. Vasopressin in Sodium Chloride Injection is generally used to increase blood pressure when other measures have failed for patients in critical hypotensive shock. Hospital pharmacies throughout the U.S. have a critical need for premix vasopressin with a long shelf life. Long Grove's new product offering will deliver immediate value to hospital pharmacies and their patients. Long Grove Pharmaceuticals introduced its first product to customers in 2022. The company is improving the generic supply chain by developing complex formulations, addressing manufacturing challenges, and achieving regulatory approvals in difficult environments. "We believe that collaborative and reliable partnerships with manufacturers, developers, suppliers, and customers are essential for sustaining a healthy drug supply chain.," explained Mr. Karas. Premix Vasopressin ordering and contracting details will be available soon. Please visit for the latest product availability information. About Long Grove Pharmaceuticals Long Grove Pharmaceuticals, LLC was established in 2019 by Water Street Healthcare Partners. The company is part of Capstone Development Services Company, LLC, which has been developing products in partnership with the world's premier pharmaceutical and medical device organizations since 2013. Combining decades of pharmaceutical and hospital leadership experience with a portfolio of specialized, complex drug formulations, Long Grove Pharmaceuticals is delivering differentiated products that increase hospital pharmacy operational efficiency and help improve the quality of patient care. SOURCE Water Street Healthcare Partners